Sandoz chief predicts big wave of biosimilars

The FDA's surprise approval of a generic version of the blood thinner Lovenox is buoying Sandoz's ambitious plans for the emerging biosimilar market. While not a protein therapy typical of biologics, Sandoz chief Jeffrey George tells Forbes that Lovenox's complex sugar structures make it hard to copy. And the agency's willingness to approve a copy will embolden others interested in making competing protein drugs. "It underscores that the FDA really does have the institutional courage to approve...